$ANIK
Anika Therapeutics, Inc. Stock $anik

$anik Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000117184321001573 Filed on March 05, 2021

Income Statement

Concept	2020 Q4	2019 Q4	2019 Q3
Revenue	$32.69M	$29.77M	$29.70M
YoY Change	9.79%	10.45%	10.86%
Cost Of Revenue	$15.94M	$8.649M	$5.951M
YoY Change	84.3%	23.54%	-28.15%
Gross Profit	$16.75M	$21.12M	$23.75M
YoY Change	-20.73%	5.89%	28.36%
Gross Profit Margin	51.23%	70.95%	79.96%
Selling, General & Admin	$15.18M	$12.24M	$7.539M
YoY Change	24.02%	99.67%	32.26%
% of Gross Profit	90.65%	57.95%	31.75%
Research & Development	$7.630M	$4.080M	$4.158M
YoY Change	87.01%	0.49%	-1.75%
% of Gross Profit	45.57%	19.32%	17.51%
Depreciation & Amortization	$3.500M	$1.530M	$1.520M
YoY Change	128.76%	3.38%	0.66%
% of Gross Profit	20.9%	7.24%	6.4%
Operating Expenses	$22.81M	$16.32M	$11.70M
YoY Change	39.77%	60.16%	17.77%
Operating Profit	-$6.065M	$4.803M	$12.05M
YoY Change	-226.28%	-50.78%	40.55%
Interest Expense	$12.31M	$360.0K	$482.0K
YoY Change	3319.44%	-34.55%	-7.66%
% of Operating Profit		7.5%	4.0%
Other Income/Expense, Net
YoY Change
Pretax Income	-$18.14M	$5.160M	$12.53M
YoY Change	-451.55%	-49.95%	37.78%
Income Tax	-$2.480M	$1.110M	$3.300M
% Of Pretax Income		21.51%	26.33%
Net Earnings	-$15.66M	$4.051M	$9.200M
YoY Change	-486.5%	-47.51%	21.07%
Net Earnings / Revenue	-47.9%	13.61%	30.98%
Basic Earnings Per Share	-$1.10	$0.28	$0.65
Diluted Earnings Per Share	-$1.10	$0.28	$0.66
COMMON SHARES
Basic Shares Outstanding	14.21M	14.27M	14.07M
Diluted Shares Outstanding	14.28M	14.62M	14.39M

Balance Sheet

Concept	2020 Q4	2019 Q4	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$98.30M	$184.9M	$173.2M
YoY Change	-46.84%	16.29%	16.24%
Cash & Equivalents	$95.82M	$157.5M	$103.4M
Short-Term Investments	$2.500M	$27.50M	$69.80M
Other Short-Term Assets	$8.800M	$4.300M	$1.500M
YoY Change	104.65%	126.32%	-25.0%
Inventory	$46.21M	$22.00M	$25.24M
Prepaid Expenses
Receivables	$24.10M	$23.08M	$23.89M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$177.4M	$234.3M	$223.8M
YoY Change	-24.29%	15.45%	14.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$50.61M	$50.78M	$51.75M
YoY Change	-0.33%	-6.15%	-5.98%
Goodwill	$8.413M	$7.694M	$7.489M
YoY Change	9.34%	-2.0%	-5.91%
Intangibles	$91.16M	$7.585M	$7.680M
YoY Change	1101.81%	-17.47%	-19.7%
Long-Term Investments
YoY Change
Other Assets	$15.42M	$7.478M	$5.761M
YoY Change	106.2%	52.71%	419.48%
Total Long-Term Assets	$188.2M	$96.40M	$95.76M
YoY Change	95.24%	26.76%	29.98%
TOTAL ASSETS
Total Short-Term Assets	$177.4M	$234.3M	$223.8M
Total Long-Term Assets	$188.2M	$96.40M	$95.76M
Total Assets	$365.6M	$330.7M	$319.6M
YoY Change	10.55%	18.54%	18.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.984M	$3.832M	$2.702M
YoY Change	134.45%	21.92%	9.75%
Accrued Expenses	$14.60M	$12.40M	$8.500M
YoY Change	17.74%	53.09%	25.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0K
YoY Change
Total Short-Term Liabilities	$36.87M	$16.28M	$11.20M
YoY Change	126.5%	44.18%	20.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.244M	$357.0K	$372.0K
YoY Change	248.46%	-35.09%	-35.19%
Total Long-Term Liabilities	$1.244M	$357.0K	$372.0K
YoY Change	248.46%	-35.09%	-35.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.87M	$16.28M	$11.20M
Total Long-Term Liabilities	$1.244M	$357.0K	$372.0K
Total Liabilities	$38.11M	$16.63M	$11.57M
YoY Change	129.12%	40.5%	17.09%
SHAREHOLDERS EQUITY
Retained Earnings	$221.4M	$245.4M	$241.4M
YoY Change	-9.77%	12.46%	14.66%
Common Stock	$55.50M	$48.85M	$46.63M
YoY Change	13.61%	-4.04%	-6.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$272.4M	$288.4M	$281.7M
YoY Change
Total Liabilities & Shareholders Equity	$365.6M	$330.7M	$319.6M
YoY Change	10.55%	18.54%	18.69%

Cashflow Statement

Concept	2020 Q4	2019 Q4	2019 Q3
OPERATING ACTIVITIES
Net Income	-$15.66M	$4.051M	$9.200M
YoY Change	-486.5%	-47.51%	21.07%
Depreciation, Depletion And Amortization	$3.500M	$1.530M	$1.520M
YoY Change	128.76%	3.38%	0.66%
Cash From Operating Activities	$2.590M	$13.03M	$10.05M
YoY Change	-80.12%	30.17%	-7.37%
INVESTING ACTIVITIES
Capital Expenditures	-$450.0K	-$270.0K	-$430.0K
YoY Change	66.67%	58.82%	-64.46%
Acquisitions
YoY Change
Other Investing Activities	$17.25M	$41.29M	$2.530M
YoY Change	-58.22%	-1806.2%	-104.69%
Cash From Investing Activities	$16.81M	$41.02M	$2.100M
YoY Change	-59.02%	-1689.92%	-103.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-28.11M	280.0K	21.70M
YoY Change	-10139.29%	-660.0%
NET CHANGE
Cash From Operating Activities	2.590M	13.03M	10.05M
Cash From Investing Activities	16.81M	41.02M	2.100M
Cash From Financing Activities	-28.11M	280.0K	21.70M
Net Change In Cash	-8.710M	54.33M	33.85M
YoY Change	-116.03%	636.18%	-176.41%
FREE CASH FLOW
Cash From Operating Activities	$2.590M	$13.03M	$10.05M
Capital Expenditures	-$450.0K	-$270.0K	-$430.0K
Free Cash Flow	$3.040M	$13.30M	$10.48M
YoY Change	-77.14%	30.65%	-13.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14329618
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1523000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	962000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1250000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1250000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-28666000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14329000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14329000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14308000
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14308000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	USD
CY2019Q4	anik	Inventory Recall Reserve InventoryRecallReserve	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95817000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	157463000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2501000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	27480000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24102000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23079000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	46209000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	21995000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8754000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4289000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	177383000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	234306000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50613000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50783000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22619000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22864000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15420000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7478000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	91157000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7585000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	8413000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	7694000	USD
CY2020Q4	us-gaap	Assets Assets	365605000	USD
CY2019Q4	us-gaap	Assets Assets	330710000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8984000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3832000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14793000	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	12445000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	13090000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36867000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16277000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1244000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	357000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	22320000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	11895000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4331000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20879000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21367000	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34336000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	42520000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	288378000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	365605000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	330710000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	130457000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114610000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	105555000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	61431000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28747000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	143000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	143000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	55355000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	48707000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4542000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5898000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	221444000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	245426000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	272400000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	31280000	USD
CY2020	us-gaap	Gross Profit GrossProfit	69026000	USD
CY2019	us-gaap	Gross Profit GrossProfit	85863000	USD
CY2018	us-gaap	Gross Profit GrossProfit	74275000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23431000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16665000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18190000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	60063000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34950000	USD
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.89
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	97348000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	51615000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	52526000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-28322000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	34248000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	21749000	USD
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-302000	USD
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1873000	USD
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1458000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28624000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	36121000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	23207000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4642000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8928000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4485000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-23982000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	27193000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	18722000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.69
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.93
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.30
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.69
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.27
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14222000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14121000
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14442000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14222000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14374000
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14689000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-23982000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	27193000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	18722000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1356000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-372000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-742000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22626000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	26821000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	17980000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	263491000	USD
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2886000	USD
CY2018	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1791000	USD
CY2018	anik	Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit	11046000	USD
CY2018	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	30000000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	18722000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-742000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	263612000	USD
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	22151000	USD
CY2019	anik	Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit	6087000	USD
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	293000	USD
CY2019	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	30000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	27193000	USD
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2020	anik	Operating Lease Rightofuse Asset Amortization OperatingLeaseRightofuseAssetAmortization	1531000	USD
CY2019	anik	Operating Lease Rightofuse Asset Amortization OperatingLeaseRightofuseAssetAmortization	1179000	USD
CY2018	anik	Operating Lease Rightofuse Asset Amortization OperatingLeaseRightofuseAssetAmortization	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	42520000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-28666000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-372000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	288378000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1524000	USD
CY2020	anik	Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit	5386000	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	262000	USD
CY2020	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	-0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-23982000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1356000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	272400000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-23982000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	27193000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	18722000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13464000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5991000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5910000	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-25000	USD
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-265000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-927000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-152000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2439000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	389000	USD
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	5386000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	6087000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	11046000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3543000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	794000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1817000	USD
CY2020	anik	Provision For Doubtful Accounts Net Of Recoveries ProvisionForDoubtfulAccountsNetOfRecoveries	549000	USD
CY2019	anik	Provision For Doubtful Accounts Net Of Recoveries ProvisionForDoubtfulAccountsNetOfRecoveries	-499000	USD
CY2018	anik	Provision For Doubtful Accounts Net Of Recoveries ProvisionForDoubtfulAccountsNetOfRecoveries	57000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	5490000	USD
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	1612000	USD
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	4419000	USD
CY2020	anik	Amortization Of Acquisition Related Inventory Step Up AmortizationOfAcquisitionRelatedInventoryStepUp	11082000	USD
CY2019	anik	Amortization Of Acquisition Related Inventory Step Up AmortizationOfAcquisitionRelatedInventoryStepUp	0	USD
CY2018	anik	Amortization Of Acquisition Related Inventory Step Up AmortizationOfAcquisitionRelatedInventoryStepUp	0	USD
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	-13000	USD
CY2019	us-gaap	Gain Loss On Investments GainLossOnInvestments	25000	USD
CY2018	us-gaap	Gain Loss On Investments GainLossOnInvestments	371000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5855000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1839000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2914000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14177000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5585000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7577000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1783000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1641000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-899000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	822000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	767000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1671000	USD
CY2020	anik	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1439000	USD
CY2019	anik	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1065000	USD
CY2018	anik	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	0	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-142000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3805000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1313000	USD
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-2072000	USD
CY2019	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1085000	USD
CY2018	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	922000	USD
CY2020	anik	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	-522000	USD
CY2019	anik	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	0	USD
CY2018	anik	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13065000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	37005000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	34918000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	94601000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-0	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-0	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	45000000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	146366000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	46000000	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	20035000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	103848000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	91601000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1628000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2827000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4656000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-71264000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	39691000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-50257000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	208000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	-0	USD
CY2018	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	-0	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	50000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	50350000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	-0	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	-0	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	-0	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	30000000	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	30000000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	262000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	293000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1790000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1524000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	22151000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2886000	USD
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	4478000	USD
CY2019	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	-0	USD
CY2018	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	-0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3774000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8142000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-28904000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	327000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-133000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-61646000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	68421000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-44214000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	157463000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	89042000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	133256000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	95817000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	157463000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	89042000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	993000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	9257000	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	5560000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	17000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	137000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	351000	USD
CY2020	anik	Consideration For Acquisitions Included In Accounts Payable And Accrued Expenses ConsiderationForAcquisitionsIncludedInAccountsPayableAndAccruedExpenses	476000	USD
CY2019	anik	Consideration For Acquisitions Included In Accounts Payable And Accrued Expenses ConsiderationForAcquisitionsIncludedInAccountsPayableAndAccruedExpenses	0	USD
CY2018	anik	Consideration For Acquisitions Included In Accounts Payable And Accrued Expenses ConsiderationForAcquisitionsIncludedInAccountsPayableAndAccruedExpenses	0	USD
CY2020	anik	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	69076000	USD
CY2019	anik	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	0	USD
CY2018	anik	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	0	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">1.</em> Nature of Business</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Anika Therapeutics, Inc. (“the Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">In early <em style="font: inherit;">2020,</em> the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC (“Parcus Medical”), a sports medicine implant and instrumentation solutions provider focused on sports medicine and soft tissue repair, and Arthrosurface Incorporated (“Arthrosurface”), a company specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened Anika's product portfolio, developed over its nearly <em style="font: inherit;">30</em> years of expertise in hyaluronic acid technology, into joint preservation and restoration, added high-growth revenue streams, increased its commercial capabilities, diversified its revenue base, and expanded its product pipeline and research and development expertise.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">There continue to be uncertainties regarding the pandemic of the novel coronavirus (“COVID-<em style="font: inherit;">19”</em>), and the Company is closely monitoring the impact of COVID-<em style="font: inherit;">19</em> on all aspects of its business, including how it will impact its customers, employees, suppliers, vendors, and business partners. The Company is unable to predict the specific impact that COVID-<em style="font: inherit;">19</em> <em style="font: inherit;"> may </em>have on its financial position and operations moving forward due to the numerous uncertainties. Any estimates made herein <em style="font: inherit;"> may </em>change as new events occur and additional information is obtained, and actual results could differ materially from any estimates made herein under different assumptions or conditions. The Company will continue to assess the evolving impact of COVID-<em style="font: inherit;">19.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company is also subject to risks common to companies in the biotechnology and medical device industries including, but <em style="font: inherit;">not</em> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p>
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:39.6pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-39.6pt;"><i>Use of Estimates</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:39.6pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p>
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1300000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-400000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-700000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	300000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-300000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-400000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	962000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1525000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1914000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	635000	USD
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6000	USD
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	57000	USD
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	86000	USD
CY2019	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	505000	USD
CY2018	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	360000	USD
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	78000	USD
CY2019	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	33000	USD
CY2018	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	-0	USD
CY2020	anik	Allowance For Doubtful Accounts Receivable Translation Adjustments AllowanceForDoubtfulAccountsReceivableTranslationAdjustments	90000	USD
CY2019	anik	Allowance For Doubtful Accounts Receivable Translation Adjustments AllowanceForDoubtfulAccountsReceivableTranslationAdjustments	-31000	USD
CY2018	anik	Allowance For Doubtful Accounts Receivable Translation Adjustments AllowanceForDoubtfulAccountsReceivableTranslationAdjustments	-86000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1523000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	962000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1525000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	200000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Concentration of Credit Risk and Significant Customers</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company has <em style="font: inherit;">no</em> significant off-balance sheet risks related to foreign exchange contracts, option contracts, or other foreign hedging arrangements. The Company’s cash equivalents and investments are held with <em style="font: inherit;">two</em> major international financial institutions.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:39.6pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Mitek represented 49% and 71% of total revenues for the years-ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> respectively. As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> Mitek represented 44% and 70%, respectively, of the Company’s accounts receivable balance; <em style="font: inherit;">no</em> other single customer accounted for more than <em style="font: inherit;">10%</em> of accounts receivable in either period.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i> </i></p>
CY2020	us-gaap	Number Of Reporting Units NumberOfReportingUnits	2	pure
CY2019	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	7144000	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2020	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	134410000	USD
CY2019	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	157728000	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-22984000	USD
CY2020Q4	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	5000000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	14852000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	12058000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12811000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8330000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	33347000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	8777000	USD
CY2020Q4	anik	Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal	61010000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	21036000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	91157000	USD
CY2019Q4	anik	Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal	29165000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	46209000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	21995000	USD
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	14801000	USD
CY2019Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	7170000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	6900000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3000000.0	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	85300000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	79293000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	34687000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28510000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50613000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50783000	USD
CY2020	us-gaap	Depreciation Depreciation	6100000	USD
CY2019	us-gaap	Depreciation Depreciation	5000000.0	USD
CY2018	us-gaap	Depreciation Depreciation	4900000	USD
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	118859000	USD
CY2020Q4	anik	Accumulated Currency Translation Adjustment AccumulatedCurrencyTranslationAdjustment	4227000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2439000	USD
CY2020	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P13Y
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	28206000	USD
CY2019Q4	anik	Accumulated Currency Translation Adjustment AccumulatedCurrencyTranslationAdjustment	4759000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	389000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15473000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7585000	USD
CY2019	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7400000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000.0	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000.0	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041	pure
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041	pure
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.050	pure
CY2019Q4	us-gaap	Goodwill Goodwill	7694000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	7851000	USD
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	719000	USD
CY2019	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-157000	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	42520000	USD
CY2019	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	42520000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	-0	USD
CY2020Q4	us-gaap	Goodwill Goodwill	8413000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	7694000	USD
CY2020	us-gaap	Number Of Reporting Units NumberOfReportingUnits	2	pure
CY2020Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18100000	USD
CY2020Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	24400000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	42500000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041	pure
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	185000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	25000	USD
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	USD
CY2020	anik	Finance Lease Expense FinanceLeaseExpense	210000	USD
CY2019	anik	Finance Lease Expense FinanceLeaseExpense	0	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2383000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	2087000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	6000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	264000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	216000	USD
CY2020	us-gaap	Lease Cost LeaseCost	2857000	USD
CY2019	us-gaap	Lease Cost LeaseCost	2309000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P15Y7M6D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P16Y9M18D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M12D
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7345000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5830000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3438000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3850000	USD
CY2020Q4	anik	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	1429000	USD
CY2019Q4	anik	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	788000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	148000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	996000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	836000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14793000	USD
CY2019Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0	pure
CY2020Q4	anik	Operating And Finance Lease Liability Undiscounted Excess Amount OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount	7816000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20879000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	356000	USD
CY2020Q4	anik	Operating And Finance Lease Liability Non Current OperatingAndFinanceLeaseLiabilityNonCurrent	21235000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2340000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1980000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	162000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2304000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	166000	USD
CY2020Q4	anik	Operating And Finance Lease Liability To Be Paid Year One OperatingAndFinanceLeaseLiabilityToBePaidYearOne	2470000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2240000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	166000	USD
CY2020Q4	anik	Operating And Finance Lease Liability To Be Paid Year Two OperatingAndFinanceLeaseLiabilityToBePaidYearTwo	2406000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2123000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	160000	USD
CY2020Q4	anik	Operating And Finance Lease Liability To Be Paid Year Three OperatingAndFinanceLeaseLiabilityToBePaidYearThree	2283000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2059000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	44000	USD
CY2020Q4	anik	Operating And Finance Lease Liability To Be Paid Year Four OperatingAndFinanceLeaseLiabilityToBePaidYearFour	2103000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1924000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	USD
CY2020Q4	anik	Operating And Finance Lease Liability To Be Paid After Year Five OperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive	1924000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	19450000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2020Q4	anik	Operating And Finance Lease Liability To Be Paid After Year Four OperatingAndFinanceLeaseLiabilityToBePaidAfterYearFour	19450000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7784000	USD
CY2020Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	32000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	130457000	USD
CY2020	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1	pure
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114610000	USD
CY2019	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1	pure
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-25722000	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	12445000	USD
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	105555000	USD
CY2018	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1	pure
CY2018	us-gaap	Inventory Recall Expense InventoryRecallExpense	1100000	USD
CY2017	us-gaap	Inventory Recall Expense InventoryRecallExpense	900000	USD
CY2020Q4	anik	Inventory Recall Reserve InventoryRecallReserve	0	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50613000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50783000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1600000
CY2019Q4	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Outstanding Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber	690968
CY2019Q4	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice	41.65
CY2020	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Grants In Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriod	546496
CY2020	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Grants In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriodWeightedAverageExercisePrice	37.78
CY2020	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Forfeitures In Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriod	112660
CY2020	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Forfeitures In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriodWeightedAverageExercisePrice	50.15
CY2020	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriod	104922
CY2020	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriodWeightedAverageExercisePrice	46.33
CY2020	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriod	123063
CY2020	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodWeightedAverageExercisePrice	12.43
CY2020Q4	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Outstanding Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber	896819
CY2020Q4	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice	41.50
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	41.50
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5500000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y4M24D
CY2020	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue	2800000	USD
CY2019	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue	8500000	USD
CY2018	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue	8500000	USD
CY2019	anik	Shares Issued Share Sharebased Payment Arrangement Nonoption Equity Instruments Exercised SharesIssuedShareSharebasedPaymentArrangementNonoptionEquityInstrumentsExercised	31541
CY2020	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedInPeriodFairValue	2500000	USD
CY2019	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedInPeriodFairValue	2700000	USD
CY2018	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedInPeriodFairValue	6700000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	16.31
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.73
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	20.01
CY2020	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	200000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	100000	USD
CY2018	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1500000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y6M
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5386000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6087000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11046000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1.40	pure
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05	pure
CY2020	anik	Defined Contribution Plan Employer Matching Contribution Amount DefinedContributionPlanEmployerMatchingContributionAmount	1700000	USD
CY2019	anik	Defined Contribution Plan Employer Matching Contribution Amount DefinedContributionPlanEmployerMatchingContributionAmount	800000	USD
CY2018	anik	Defined Contribution Plan Employer Matching Contribution Amount DefinedContributionPlanEmployerMatchingContributionAmount	800000	USD
CY2019Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	50000000.0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	13972000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	38299000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	26227000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2902000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2178000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3020000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28624000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	36121000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	23207000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	357000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6245000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	4783000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-1970000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1884000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1644000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	49000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	202000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	405000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-1564000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	8331000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6832000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1980000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1086000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-992000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1070000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	324000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-152000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-28000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-813000	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1203000	USD
CY2020	anik	Deferred Income Tax Expense Benefit Foreign And Domestic Net DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet	-3078000	USD
CY2019	anik	Deferred Income Tax Expense Benefit Foreign And Domestic Net DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet	597000	USD
CY2018	anik	Deferred Income Tax Expense Benefit Foreign And Domestic Net DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet	-2347000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4642000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8928000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4485000	USD
CY2020Q4	anik	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	5147000	USD
CY2019Q4	anik	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	5206000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	2004000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1187000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4775000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1812000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1742000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1901000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2485000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	229000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	346000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	156000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1076000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16538000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11528000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	857000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11528000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	-0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15681000	USD
CY2020	anik	Effective Income Tax Rate Reconciliation Change In State Apportionment Percent EffectiveIncomeTaxRateReconciliationChangeInStateApportionmentPercent	0.049	pure
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	2023000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8493000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8665000	USD
CY2020Q4	anik	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	5111000	USD
CY2019Q4	anik	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	5171000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	27576000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	15859000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	11895000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	11900000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.015	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.055	pure
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.055	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.022	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.009	pure
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.005	pure
CY2020	anik	Effective Income Tax Rate Reconciliation Goodwill Impairment Percent EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent	-0.168	pure
CY2019	anik	Effective Income Tax Rate Reconciliation Goodwill Impairment Percent EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent	0.000	pure
CY2018	anik	Effective Income Tax Rate Reconciliation Goodwill Impairment Percent EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent	0.000	pure
CY2020	anik	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsiderationPercent	0.067	pure
CY2019	anik	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsiderationPercent	0.000	pure
CY2018	anik	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsiderationPercent	0.000	pure
CY2019	anik	Effective Income Tax Rate Reconciliation Change In State Apportionment Percent EffectiveIncomeTaxRateReconciliationChangeInStateApportionmentPercent	0.000	pure
CY2018	anik	Effective Income Tax Rate Reconciliation Change In State Apportionment Percent EffectiveIncomeTaxRateReconciliationChangeInStateApportionmentPercent	0.000	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.022	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.015	pure
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.036	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.030	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.000	pure
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.000	pure
CY2020	anik	Effective Income Tax Reconciliation Nondeductible Expenses Permanent Items Percent EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent	0.019	pure
CY2019	anik	Effective Income Tax Reconciliation Nondeductible Expenses Permanent Items Percent EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent	-0.012	pure
CY2018	anik	Effective Income Tax Reconciliation Nondeductible Expenses Permanent Items Percent EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent	-0.031	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.162	pure
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.247	pure
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.193	pure
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2019	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	253199
CY2018	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	247505
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14222163
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14373783
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14689041
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14222163
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14120584
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14441536
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32688000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31694000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30678000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35397000	USD
CY2020Q4	us-gaap	Gross Profit GrossProfit	16745000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	17343000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	13742000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	21196000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-15657000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-6411000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-7708000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	5794000	USD
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.10
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.41
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.10
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
CY2020Q4	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14275000
CY2020Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14205000
CY2020Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14199000
CY2020Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14202000
CY2020Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14275000
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14205000
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14199000
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14353000
CY2020Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18100000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-24500000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4200000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4100000	USD
CY2020Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	24400000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-12500000	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29772000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29697000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30418000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24723000	USD
CY2019Q4	us-gaap	Gross Profit GrossProfit	21123000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	23746000	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	23582000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	17412000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	4051000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	9200000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	9435000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	4507000	USD
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.65
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.68
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.66
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.67
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
CY2019Q4	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14280000
CY2019Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14070000
CY2019Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	13916000
CY2019Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14185000
CY2019Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14621000
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14387000
CY2019Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14088000
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14314000

Files In Submission

Name	View Source	Status
0001171843-21-001573-index-headers.html	Edgar Link	pending
0001171843-21-001573-index.html	Edgar Link	pending
0001171843-21-001573.txt	Edgar Link	pending
0001171843-21-001573-xbrl.zip	Edgar Link	pending
anik-20201231.xsd	Edgar Link	pending
anik-20201231_cal.xml	Edgar Link	unprocessable
anik-20201231_def.xml	Edgar Link	unprocessable
anik-20201231_lab.xml	Edgar Link	unprocessable
anik-20201231_pre.xml	Edgar Link	unprocessable
anik20201231_10k.htm	Edgar Link	pending
anik20201231_10kimg001.gif	Edgar Link	pending
anik20201231_10k_htm.xml	Edgar Link	completed
ex_231248.htm	Edgar Link	pending
ex_231249.htm	Edgar Link	pending
ex_231250.htm	Edgar Link	pending
ex_231421.htm	Edgar Link	pending
ex_231631.htm	Edgar Link	pending
ex_231632.htm	Edgar Link	pending
ex_231633.htm	Edgar Link	pending
ex_231634.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIK
Anika Therapeutics, Inc. Stock $anik

2020 Q4 Form 10-K Financial Statement

#000117184321001573 Filed on March 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIK Anika Therapeutics, Inc. Stock $anik

2020 Q4 Form 10-K Financial Statement

#000117184321001573 Filed on March 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIK
Anika Therapeutics, Inc. Stock $anik